Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease

AIDS

Volumn 14, Issue 7, 2000, Pages 761-770

  Al Harthi, Lena ^a,e   Siegel, Joan ^a   Spritzler, John ^b   Pottage, John ^c,d   Agnoli, Michelle ^c   Landay, Alan ^a,c  

^a Dept of Immunology/Microbiology ^*  (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Division of Infectious Disease   (United States)

^d VERTEX PHARMACEUTICALS   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Advanced HIV disease; Early HIV disease; Highly active antiretroviral therapy; HIV; Immune function; Immune reconstitution; Inducible cytokines; Lymphocyte proliferation assay; p24 response

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; CD38 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; FAS ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; INDINAVIR; INTERLEUKIN 12; LAMIVUDINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES; ZIDOVUDINE;

APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOPHENOTYPING; LYMPHOCYTE PROLIFERATION; MEMORY CELL; MULTICENTER STUDY; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS IMMUNITY; VIRUS REPLICATION;

EID: 0034110009     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200005050-00001     Document Type: Article

References (37)

1. 1. Lane HC, Depper JM, Greene WC, Whalen G, Waldmann TA, Fauci AS. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med 1985, 313:79-84.
2. 2. Clerici M, Stocks NI, Zajac RA, et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. J Clin Invest 1989, 84:1892-1899.
3. 3. Valdez H, Lederman MM. Cytokines and cytokine therapies in HIV infection. AIDS Clin Rev 1997, :187-228.
4. 4. Cohen OJ, Kinter A, Fauci AS. Host factors in the pathogenesis of HIV disease. Immunol Rev 1997, 159:31-48.
5. 5. Clerici M, Shearer GM. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today 1994, 15:575-581.
6. 6. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
7. 7. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998, 178:70-79.
8. 8. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
9. 9. Bisset LR, Cone RW, Huber W, et al. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study. AIDS 1998, 12:2115-2123.
10. 10. Evans TG, Bonnez W, Soucier HR, Fitzgerald T, Gibbons DC, Reichman RC. Highly active antiretroviral therapy results in a decrease in CD8+ T cell activation and preferential reconstitution of the peripheral CD4+ T cell population with memory rather than naive cells. Antiviral Res 1998, 39:163-173.
11. 11. Mezzaroma J, Carlesimo M, Pinter E, et al. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease. AIDS 1999, 13:1187-1193.
12. 12. Pakker NG, Roos MT, van Leeuwen R, et al. Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16:318-326.
13. 13. Rinaldo Jr CR, Liebmann JM, Huang XL, et al. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. J Infect Dis 1999, 179:329-336.
14. 14. Kelleher AD, Al-Harthi L, Landay AL. Immunological effects of antiretroviral and immune therapies for HIV. AIDS 1997, 11(Suppl A):S149-S155.
15. 15. Valdez H, Al-Harthi L, Landay A, Lederman MM. Rationale for immune-based therapies for HIV-1 infection. J Lab Clin Med 1998, 131:197-206.
16. 16. Sousa AE, Chaves AF, Doroana M, Antunes F, Victorino RM. Kinetics of the changes of lymphocyte subsets defined by cytokine production at single cell level during highly active antiretroviral therapy for HIV-1 infection. J Immunol 1999, 162:3718-3726.
17. 17. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998, 4:208-214.
18. 18. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998, 396:690-695.
19. 19. Lewin S, Kostrikis L, Karanicolas R, et al. The impact of HIV infection on the number of recent thymic emigrants in blood and the effect of HAART. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January-February 1999.
20. 20. Roeder M, De Rosa SC, Watanabe N, Herzenberg LA, Herzenberg LA. Dynamics of fime T-cell subsets during HIV disease and after thymic ablation by mediastinal irradiation. Semin Immunol 1997, 9:389-396.
21. 21. Weinberg A, Betensky RA, Zhang L, Ray G. Effect of shipment, storage, anticoagulant, and cell separation on lymphocyte proliferation assays for human immunodeficiency virus-infected patients. Clin Diagn Lab Immunol 1998, 5:804-807.
22. 22. Gray CM, Schapiro JM, Winters MA, Merigan TC. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience. AIDS Res Hum Retroviruses 1998, 14:561-569.
23. 23. Lane H, Gea-Banacloche J. Immune reconstitution in HIV infection. AIDS 1999, 13:S25-S38.
24. 24. Zaunders JJ, Cunningham PH, Kelleher AD, et al. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia. J Infect Dis 1999, 180:320-329.
25. 25. Poulin J-F, Viswanathan MN, Harris JM, et al. Direct evidence for thymic function in adult human. J Exp Med 1999, 190:479-486.
26. 26. Steffens C, Marchetti G, Landay A, Al-Harthi L. The human thymus: a new perspective on thymic function, aging, and HIV infection. Clin Immun News Letter 1999, 19:65-74.
27. 27. Oyaizu N, Pahwa S. Role of apoptosis in HIV pathogenesis. J Clin Immunol 1995, 15:217-222.
28. 28. Debatin KM, Fahrig-Faissner A, Enenkel-Stoodt S, Kreuz W, Benner A, Krammer PH. High expression of APO-1 (CD95) on T lymphocytes from human immunodeficiency virus-1-infected children [letter]. Blood 1994, 83:3101-3103.
29. 29. Sloand EM, Young NS, Kumar P, Weichold FF, Sato T, Maciejewski JP. Role of Fas ligand and receptor in the mechanism of T-cell depletion in acquired immunodeficiency syndrome: effect on CD4+ lymphocyte depletion and human immunodeficiency virus replication. Blood 1997, 89:1357-1363.
30. 30. Sloand EM, Maciejevvski JP, Tadatsugu S, Brunny J, Kumar P, Kim S. The role of interleukin-converting enzyme in Fas-mediated apoptosis in HIV-1 infection. J Clin Invest 1998, 101.
31. 31. Kelleher AD, Roggensack M, Emery S, Carr A, French MA, Cooper DA. Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens. Clin Exp Immunol 1998, 113: 85-91.
32. 32. Plana M, Garcia F, Gallart T, Miro JM, Gatell JM. Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology Study Group of Spanish EARTH-1 Study [letter]. Lancet 1998, 352:1194-1195.
33. 33. Pontesilli O, Kerkhof-Garde S, Pakker NG, et al. Antigen-specific T-lymphocyte proliferative responses during highly active antiretroviral therapy (HAART) of HIV-1 infection. Immunol Lett 1999, 66:213-217.
34. 34. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1 -specific CD4+ T cell responses associated with control of viremia. Science 1997, 278:1447-1450.
35. 35. Bailer RT, Holloway A, Sun J, et al. IL-13 and IFN-gamma secretion by activated T cells in HIV-1 infection associated with viral suppression and a lack of disease progression. J Immunol 1999, 162:7534-7542.
36. 36. Conlon K, Lloyd A, Chattopadhyay U, et al. CD8+ and CD45RA+ human peripheral blood lymphocytes are potent sources of macrophage inflammatory protein 1 alpha, interleukin-8 and RANTES. Eur J Immunol 1995, 25:751-756.
37. 37. Price DA, Sewell AK, Dong T, et al. Antigen-specific release of beta-chemokines by anti-HIV-1 cytotoxic T lymphocytes. Curr Biol1998, 8:355-358.